Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

March 31, 2024

Conditions
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
Interventions
DRUG

KRT-232

KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth

DRUG

acalabrutinib

acalabrutinib is a BTK inhibitor anticancer drug taken by mouth

Trial Locations (45)

43210

RECRUITING

The Ohio State University Comprehensive Cancer Center, Columbus

45221

RECRUITING

University of Cincinnati, Cincinnati

46526

RECRUITING

Goshen Center for Cancer Care, Goshen

75390

RECRUITING

UT Southwestern Medical Center, Dallas

Unknown

RECRUITING

Royal Adelaide Hospital, Adelaide

RECRUITING

Eastern Health - Box Hill Hospital, Box Hill

RECRUITING

Barwon Health, Geelong

RECRUITING

Royal Perth Hospital, Perth

RECRUITING

Antwerp University Hospital (UZA), Edegem

RECRUITING

Jessa Ziekenhuis, Hasselt

RECRUITING

University Hospital (UZ) Leuven, Leuven

RECRUITING

Fakultni Nemocnice Hradec Kralove, Nový Hradec Králové

RECRUITING

Fakultni nemocnice Ostrava, Ostrava

RECRUITING

Vseobecna fakultni nemocnice v Praze, Prague

RECRUITING

CHU de Nantes - Hôtel-Dieu, Nantes

RECRUITING

Centre Henri Becquerel, Rouen

RECRUITING

CHRU de Tours - Hôpital Bretonneau, Tours

RECRUITING

Centro Riferimento Oncologico - Aviano, Aviano

RECRUITING

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola

RECRUITING

ASST Grande Ospedale Metropolitano Niguarda, Milan

RECRUITING

IRCCS Ospedale San Raffaele, Milan

RECRUITING

Fondazione IRCCS Policlinico San Matteo, Pavia

RECRUITING

Centro Ricerche Cliniche di Verona s.r.l., Verona

RECRUITING

Copernicus PL Sp. z o.o., Wojewodzkie Centrum Onkologii, Gdansk

RECRUITING

Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii, Gdansk

RECRUITING

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach - Klinika Transplantacji Szpiku i Onkohematologii, Gliwice

RECRUITING

Pratia MCM Krakow, Krakow

RECRUITING

Szpital Uniwersytecki Krakow - Oddzial Kliniczny Hematologii, Krakow

RECRUITING

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu, Wroclaw

RECRUITING

Hospital de Braga, Braga

RECRUITING

Centro Hospitalar Universitario de Lisboa Norte - Hospital de Santa Maria, Lisbon

RECRUITING

Champalimaud Cancer Center, Lisbon

RECRUITING

Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE, Porto

RECRUITING

Centro Hospitalar de Vila Nova de Gaia/Espinho EPE, Vila Nova de Gaia

RECRUITING

National Cancer Center, Goyang

RECRUITING

Gachon University Gil Medical Center, Incheon

RECRUITING

Samsung Medical Center, Seoul

RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Seoul St. Mary's Hospital, Seoul

RECRUITING

Severance Hospital, Yonsei University Health System, Seoul

RECRUITING

Kantonsspital St. Gallen, Sankt Gallen

RECRUITING

St James's University Hospital, Leeds

RECRUITING

King's College Hospital, London

RECRUITING

Royal Marsden Foundation Trust, London

RECRUITING

University Hospital Southampton NHS Foundation Trust, Southampton

Sponsors
All Listed Sponsors
lead

Kartos Therapeutics, Inc.

INDUSTRY

NCT04502394 - Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | Biotech Hunter | Biotech Hunter